Tandem Diabetes Care Stock News

Tandem Diabetes Care, Inc. (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Tandem Diabetes (TNDM) witnesses strong customer retention, driven by the impressive positive response from the Control-IQ technology.

Tandem Diabetes (TNDM) witnesses strong customer retention, driven by the impressive positive response from the Control-IQ technology.

Biopharmaceutical stocks have undergone a dramatic correction over the past six months, with the XBI declining by 45%. I highlight stocks that are attractively priced.

Within the last quarter, Tandem Diabetes Care (NASDAQ:TNDM) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 2 0 0

Robust pump shipments and growth in the installed customer base are driving Tandem Diabetes' (TNDM) first-quarter top line.

Robust pump shipments and growth in the installed customer base are driving Tandem Diabetes' (TNDM) first-quarter top line.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Susan Morrison - EVP and Chief Administrative Officer John Sheridan - President a

Veracyte (VCYT) delivered earnings and revenue surprises of 13.04% and 9.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Tandem Diabetes Care has steadily improved its company revenue in each of the last four years.

Don't be too quick to jump on the Shiba Inu bandwagon.

Tandem Diabetes Care Inc (NASDAQ: TNDM ) reported Q4 sales reached $209.9 million , +25% Y/Y, beating the consensus of $199.12 million. The Company posted EPS of $0.16, down from $0.22 a year ago, and missed the Wall Street estimate of $0.21. Worldwide pump shipments … Full story available on Benzinga.com

Over the past 3 months, 4 analysts have published their opinion on Tandem Diabetes Care (NASDAQ:TNDM) stock. These analysts are typically employed by large Wall Street banks and tasked with understand

Over the past 3 months, 4 analysts have published their opinion on Tandem Diabetes Care (NASDAQ: TNDM ) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company''s business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 2 1 0 0 Last 30D 1 1 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 1 0 0 0 3M Ago 0 0 0 0 0 According to 4 analyst offering 12-month price targets in the last 3 months, Tandem Diabetes Care has an average price target of $150.25 with a high of $166.00 and a low of $120.00. Below is … Full story available on Benzinga.com

Robust domestic and international pump shipments are driving Tandem Diabetes' (TNDM) fourth-quarter top line.